- Home
- NEOV vs RCEL Comparison
NEOV vs RCEL Comparison
Compare NEOV & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- RCEL
- Stock Information
- Founded
- NEOV 2018
- RCEL N/A
- Country
- NEOV United States
- RCEL United States
- Employees
- NEOV N/A
- RCEL N/A
- Industry
- NEOV Industrial Machinery/Components
- RCEL Medical/Dental Instruments
- Sector
- NEOV Miscellaneous
- RCEL Health Care
- Exchange
- NEOV Nasdaq
- RCEL Nasdaq
- Market Cap
- NEOV 153.9M
- RCEL 140.5M
- IPO Year
- NEOV N/A
- RCEL N/A
- Fundamental
- Price
- NEOV $5.72
- RCEL N/A
- Analyst Decision
- NEOV Hold
- RCEL Strong Buy
- Analyst Count
- NEOV 1
- RCEL 4
- Target Price
- NEOV N/A
- RCEL $13.75
- AVG Volume (30 Days)
- NEOV 376.6K
- RCEL 1.3M
- Earning Date
- NEOV 11-07-2025
- RCEL 11-06-2025
- Dividend Yield
- NEOV N/A
- RCEL N/A
- EPS Growth
- NEOV N/A
- RCEL N/A
- EPS
- NEOV N/A
- RCEL N/A
- Revenue
- NEOV $8,426,835.00
- RCEL $74,884,000.00
- Revenue This Year
- NEOV $121.51
- RCEL $22.92
- Revenue Next Year
- NEOV $32.79
- RCEL $37.07
- P/E Ratio
- NEOV N/A
- RCEL N/A
- Revenue Growth
- NEOV 218.59
- RCEL 38.32
- 52 Week Low
- NEOV $1.80
- RCEL $3.60
- 52 Week High
- NEOV $6.11
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- NEOV 64.24
- RCEL 54.48
- Support Level
- NEOV $4.65
- RCEL $5.03
- Resistance Level
- NEOV $5.05
- RCEL $5.64
- Average True Range (ATR)
- NEOV 0.45
- RCEL 0.34
- MACD
- NEOV 0.01
- RCEL 0.01
- Stochastic Oscillator
- NEOV 89.56
- RCEL 49.00
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.